FDA Approves Juvmo for Parkinson’s Disease
Originally published by our sister publication Specialty Pharmacy ContinuumBy SPC StaffThe FDA approved tavapadon (Juvmo, AbbVie) tablets for adults with Parkinson’s disease. The drug is the first selective D1/D5 receptor agonist approved for the disease.The approval was based on data from the TEMPO-3 trial (ClinicalTrials.gov Identifer: NCT04542499) published in JAMA Neurology (2026;83;[5]:442-451).“Development of motor fluctuations is common in people with [Parkinson’s diseas
Read more »